| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO 80262;
Department of Internal Medicine and Pathology, Pulmonary and Critical Care Medicine Division, Ann Arbor Veterans Affairs Medical Center and University of Michigan Medical Center, Ann Arbor, MI 48109; and
Department of Specialty Care Services, University of Texas Health Center, Tyler, TX 75708
Urokinase plasminogen activator (uPA) is a serine protease that catalyzes the conversion of plasminogen to plasmin. Although increased circulating levels of uPA are present in endotoxemia and sepsis, conditions in which activated neutrophils contribute to the development of acute organ dysfunction, the ability of uPA to participate directly in LPS-induced neutrophil activation has not been examined. In the present experiments, we show that uPA can enhance activation of neutrophils exposed to submaximal stimulatory doses of LPS. In particular, uPA increased LPS-induced activation of intracellular signaling pathways, including Akt and c-Jun N-terminal kinase, nuclear translocation of the transcriptional regulatory factor NF-
B, and expression of proinflammatory cytokines, including IL-1
, macrophage-inflammatory protein-2, and TNF-
. There was no effect of uPA on LPS-induced activation of p38 mitogen-activated protein kinase in neutrophils. Transgenic mice unable to produce uPA (uPA-/-) were protected from endotoxemia-induced lung injury, as determined by development of lung edema, pulmonary neutrophil accumulation, lung IL-1, macrophage-inflammatory protein-2, and TNF- cytokine levels. These results demonstrate that uPA can potentiate LPS-induced neutrophil responses and also suggest that such effects are sufficiently important in vivo to play a major contributory role in neutrophil-mediated inflammatory responses, such as the development of acute lung injury.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  F. Gueler, S. Rong, M. Mengel, J.-K. Park, J. Kiyan, T. Kirsch, I. Dumler, H. Haller, and N. Shushakova Renal Urokinase-Type Plasminogen Activator (uPA) Receptor but not uPA Deficiency Strongly Attenuates Ischemia Reperfusion Injury and Acute Kidney Allograft Rejection J. Immunol., July 15, 2008; 181(2): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsuruta, Y.-J. Park, G. P. Siegal, G. Liu, and E. Abraham Involvement of Vitronectin in Lipopolysaccaride-Induced Acute Lung Injury J. Immunol., November 15, 2007; 179(10): 7079 - 7086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suelves, B. Vidal, A. L. Serrano, M. Tjwa, J. Roma, R. Lopez-Alemany, A. Luttun, M. M. de Lagran, M. A. Diaz, M. Jardi, et al. uPA deficiency exacerbates muscular dystrophy in MDX mice J. Cell Biol., September 7, 2007; 178(6): 1039 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Begin, K. Tremblay, D. Daley, M. Lemire, S. Claveau, C. Salesse, S. Kacel, A. Montpetit, A. Becker, M. Chan-Yeung, et al. Association of Urokinase-type Plasminogen Activator with Asthma and Atopy Am. J. Respir. Crit. Care Med., June 1, 2007; 175(11): 1109 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shetty, T. Velusamy, S. Idell, H. Tang, and P. K. Shetty Regulation of urokinase receptor expression by protein tyrosine phosphatases Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L414 - L421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Renckens, J. M. Pater, and T. v. d. Poll Plasminogen Activator Inhibitor Type-1-Deficient Mice Have an Enhanced IFN-{gamma} Response to Lipopolysaccharide and Staphylococcal Enterotoxin B J. Immunol., December 1, 2006; 177(11): 8171 - 8176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Wang, K. Bdeir, S. Yarovoi, D. B. Cines, W. Fang, and E. Abraham Involvement of the Urokinase Kringle Domain in Lipopolysaccharide-Induced Acute Lung Injury J. Immunol., October 15, 2006; 177(8): 5550 - 5557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Huber, O. Distler, I. Tarner, R. E. Gay, S. Gay, and T. Pap Synovial fibroblasts: key players in rheumatoid arthritis Rheumatology, June 1, 2006; 45(6): 669 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Kwak, S. Mitra, K. Bdeir, D. Strassheim, J. S. Park, J. Y. Kim, S. Idell, D. Cines, and E. Abraham The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins J. Leukoc. Biol., October 1, 2005; 78(4): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shushakova, G. Eden, M. Dangers, J. Zwirner, J. Menne, F. Gueler, F. C. Luft, H. Haller, and I. Dumler The Urokinase/Urokinase Receptor System Mediates the IgG Immune Complex-Induced Inflammation in Lung J. Immunol., September 15, 2005; 175(6): 4060 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Koh, S. C. Bryer, A. M. Pucci, and T. H. Sisson Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration Am J Physiol Cell Physiol, July 1, 2005; 289(1): C217 - C223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shushakova, N. Tkachuk, M. Dangers, S. Tkachuk, J.-K. Park, K. Hashimoto, H. Haller, and I. Dumler Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor J. Cell Sci., June 15, 2005; 118(12): 2743 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Nick, C. D. Coldren, M. W. Geraci, K. R. Poch, B. W. Fouty, J. O'Brien, M. Gruber, S. Zarini, R. C. Murphy, K. Kuhn, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis Blood, December 15, 2004; 104(13): 3878 - 3885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Gyetko, D. Aizenberg, and L. Mayo-Bond Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro J. Leukoc. Biol., September 1, 2004; 76(3): 648 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Park, D. Svetkauskaite, Q. He, J.-Y. Kim, D. Strassheim, A. Ishizaka, and E. Abraham Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein J. Biol. Chem., February 27, 2004; 279(9): 7370 - 7377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Idell The Matrix Unloaded: Aerosolized Heparin or Urokinase for Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1268 - 1269. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
